Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Four Treatment Modalities in Prostate Cancer With Low or Early Intermediate Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed, biopsy proven adenocarcinoma of the prostate (ultrasound guided biopsy by standardized protocol)~* Men aged 18-75 years~* Recruitment within 3 months after histological confirmation~* Localized prostata cancer \<= cT2a, NX or N0 M0~* PSA \<= 10 ng / ml~* Gleason score \<= 7a (3 +4)~* ECOG performance status 0 or 1~* \<= 30% positive biopsy cores with largest contiguous tumor length \<= 5 mm~* IPSS score \< 18~* Urine flow (Qmax):\> 15 ml / s~Exclusion Criteria:~* Unifocal Gleason 6 cancer \<1mm~* History of treatment for BPH e.g. TURP, HIFU or cryotherapy~* History of radiation therapy to the pelvis~* Life expectancy \<10 years~* ASA \>= 4~* Post-void residual urine \> 50 ml~* Prostate volume on transrectal ultrasound \> 60 cm3~* large median prostate lobe visualized on transrectal ultrasound~* chronic intestinal inflammatory disease covering the rectum~* Other active malignancy within the past 5 years (except for superficial basal cell carcinoma or non muscle infiltrating bladder carcinoma)~* contraindications for prostatectomy, radiation therapy or Active Surveillance~* Patients refusing written informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- radical prostatectomy (Type: EXPERIMENTAL): Procedure/Surgery: radical prostatectomy
- percutaneous radiation therapy (Type: EXPERIMENTAL): Radiation: percutaneous radiation therapy
- permanent seed implantation (Type: EXPERIMENTAL): Radiation: permanent seed implantation
- Active Surveillance (Type: EXPERIMENTAL): Procedure/Surgery: Active Surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).